Suppr超能文献

利用SAr化学的亲电降解剂的发现。

Discovery of electrophilic degraders that exploit SAr chemistry.

作者信息

Zhuang Zhe, Byun Woong Sub, Kozicka Zuzanna, Dwyer Brendan G, Donovan Katherine A, Jiang Zixuan, Jones Hannah M, Abeja Dinah M, Nix Meredith N, Zhong Jianing, Słabicki Mikołaj, Fischer Eric S, Ebert Benjamin L, Gray Nathanael S

机构信息

Department of Chemical and Systems Biology, ChEM-H, and Stanford Cancer Institute, Stanford School of Medicine, Stanford University, Stanford, CA, USA.

These authors contributed equally: Zhe Zhuang, Woong Sub Byun.

出版信息

bioRxiv. 2024 Sep 27:2024.09.25.615094. doi: 10.1101/2024.09.25.615094.

Abstract

Targeted covalent inhibition (TCI) and targeted protein degradation (TPD) have proven effective in pharmacologically addressing formerly 'undruggable' targets. Integration of both methodologies has resulted in the development of electrophilic degraders where recruitment of a suitable E3 ubiquitin ligase is achieved through formation of a covalent bond with a cysteine nucleophile. Expanding the scope of electrophilic degraders requires the development of electrophiles with tempered reactivity that enable selective ligase recruitment and reduce cross-reactivity with other cellular nucleophiles. In this study, we report the use of chemical moieties that enable nucleophilic aromatic substitution (SAr) reactions in the rational design of electrophilic protein degraders. Appending an SAr covalent warhead to several preexisting small molecule inhibitors transformed them into degraders, obviating the need for a defined E3 ligase recruiter. The SAr covalent warhead is versatile; it can recruit various E3 ligases, including DDB1 and CUL4 associated factor 11 (DCAF11), DDB1 and CUL4 associated factor 16 (DCAF16), and possibly others. The incorporation of an SAr covalent warhead into the BRD4 inhibitor led to the discovery of degraders with low picomolar degradation potency. Furthermore, we demonstrate the broad applicability of this approach through rational functional switching from kinase inhibitors into potent degraders.

摘要

靶向共价抑制(TCI)和靶向蛋白质降解(TPD)已被证明在药理学上能够有效应对以前“不可成药”的靶点。将这两种方法结合起来,已促成了亲电降解剂的开发,即通过与半胱氨酸亲核试剂形成共价键来实现合适的E3泛素连接酶的募集。扩大亲电降解剂的范围需要开发具有适度反应性的亲电试剂,以实现选择性连接酶募集并减少与其他细胞亲核试剂的交叉反应。在本研究中,我们报告了在亲电蛋白质降解剂的合理设计中使用能够实现亲核芳香取代(SAr)反应的化学基团。在几种现有的小分子抑制剂上附加一个SAr共价弹头,将它们转化为降解剂,从而无需特定的E3连接酶招募剂。SAr共价弹头具有通用性;它可以募集各种E3连接酶,包括DDB1和CUL4相关因子11(DCAF11)、DDB1和CUL4相关因子16(DCAF16),以及可能的其他酶。将SAr共价弹头引入BRD4抑制剂中,发现了具有低皮摩尔降解效力的降解剂。此外,我们通过从激酶抑制剂到强效降解剂的合理功能转换,证明了这种方法的广泛适用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/817d/11463635/f47fb9a8158b/nihpp-2024.09.25.615094v1-f0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验